Faron Pharmaceuticals H1 2023: Clinical advancements - Redeye

Redeye provides a research update on Faron Pharmaceuticals following the company’s recent half-year report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our estimates for OPEX following a slightly lower cash burn than expected. However, we reiterate our base case valuation as we continue to see a compelling case rooted in an exciting clinical pipeline.

Länk till analysen i sin helhet: https://www.redeye.se/research/940001/faron-pharmaceuticals-h1-2023-clinical-advancements?utm_source=finwire&utm_medium=RSS